SUVN-D4010

5-HT_4 Partial Agonist

Dual Mechanism of Action (Disease Modifying and Symptomatic Treatment Potential for AD)

Phase 1 Completed in USA; Ready for Phase 2 POC

SUVEN Life Sciences

SUVN-D4010: Key Features

- Selective serotonin-4 receptor (5-HT_4) partial agonist
- Orally bioavailable with good brain penetration
- Good correlation between affinity, free fraction and efficacy
- Clean in hERG, phospholipidosis and AMES assays
- No QT/QTc prolongation in dog telemetry study
- Robust efficacy in animal models
- Potentiates the efficacy of cholinesterase inhibitors in animal models
- Disease modifying effects in animal models
- Translatable biomarker available for POC study
- Good margin of safety in preclinical studies
- No genotoxicity and teratogenic potential
- Well protected intellectual property in all major markets
- Safe and well tolerated in healthy adult subjects (Phase-1 study)
- Excellent human pharmacokinetics suitable for once a day treatment
- Projected human efficacy concentrations achieved in Phase-1 study
- No effect of food, gender and age on human pharmacokinetics

SUVN-D4010: Key Pharmacology Results

Target Engagement in Rats



Object Recognition Task in Rats



Modulation of sAPPα Levels



Disease Modifying and Symptomatic Treatment Potential for Alzheimer's Disease

SUVN-D4010: Clinical Studies Summary and Current Status

- Well tolerated in humans with dose dependent pharmacokinetics
- Suitable for once a day oral dosing
- Projected human efficacy concentrations achieved at low doses in Phase 1 study

Current status: Phase 1 Completed in USA; Ready for Phase 2 POC

Contacts:

Venkat Jasti

Chairman & CEO

E-mail: info@suven.com

Ramakrishna Nirogi

Vice President, Discovery Research

E-mail: nvsrk@suven.com